scholarly journals Apraglutide, a novel glucagon‐like peptide 2 analog, improves fluid absorption in patients with short bowel syndrome intestinal failure: findings from a placebo‐controlled, randomized phase 2 trial

2021 ◽  
Author(s):  
Johanna Eliasson ◽  
Mark K Hvistendahl ◽  
Nanna Freund ◽  
Federico Bolognani ◽  
Christian Meyer ◽  
...  
Keyword(s):  
Short Bowel Syndrome ◽  
Intestinal Failure ◽  
Phase 2 ◽  
Fluid Absorption ◽  
Short Bowel ◽  
Phase 2 Trial ◽  
Glucagon Like Peptide ◽  
Randomized Phase 2

Safety and efficacy of apraglutide in patients with short bowel syndrome intestinal failure: a double-blind, crossover, randomized, placebo-controlled, phase 2 trial

2020 ◽  
Vol 40 ◽  
pp. 436
Author(s):  
J. Eliasson ◽  
M.K. Hvistendahl ◽  
C. Meyer ◽  
F. Bolognani ◽  
P.B. Jeppesen
Keyword(s):  
Short Bowel Syndrome ◽  
Intestinal Failure ◽  
Phase 2 ◽  
Double Blind ◽  
Safety And Efficacy ◽  
Short Bowel ◽  
Phase 2 Trial

scholarly journals Effects of glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, on markers of liver status in patients with short bowel syndrome: findings from a randomised phase 2 trial

EBioMedicine ◽  
2019 ◽  
Vol 46 ◽  
pp. 444-451 ◽  
Author(s):  
Rahim Mohammad Naimi ◽  
Mark Hvistendahl ◽  
Nikolaj Nerup ◽  
Rikard Ambrus ◽  
Michael Patrick Achiam ◽  
...  
Keyword(s):  
Short Bowel Syndrome ◽  
Phase 2 ◽  
Short Bowel ◽  
Phase 2 Trial ◽  
Glucagon Like Peptide ◽  
Long Acting

Glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial

2019 ◽  
Vol 4 (5) ◽  
pp. 354-363 ◽  
Author(s):  
Rahim M Naimi ◽  
Mark Hvistendahl ◽  
Lotte H Enevoldsen ◽  
Jan L Madsen ◽  
Stefan Fuglsang ◽  
...  
Keyword(s):  
Short Bowel Syndrome ◽  
Phase 2 ◽  
Short Bowel ◽  
Phase 2 Trial ◽  
Glucagon Like Peptide ◽  
Long Acting

Su2007 APRAGLUTIDE, A NOVEL LONG-ACTING GLUCAGON-LIKE PEPTIDE-2 ANALOG, IN THE TREATMENT OF PATIENTS WITH SHORT BOWEL SYNDROME: AN OPEN-LABEL PHASE 2 TRIAL

2020 ◽  
Vol 158 (6) ◽  
pp. S-741-S-742
Author(s):  
Johanna Eliasson ◽  
Mark Hvistendahl ◽  
Federico Bolognani ◽  
Christian Meyer ◽  
Palle B. Jeppesen
Keyword(s):  
Short Bowel Syndrome ◽  
Phase 2 ◽  
Open Label ◽  
Short Bowel ◽  
Phase 2 Trial ◽  
Open Label Phase ◽  
Glucagon Like Peptide ◽  
Long Acting

scholarly journals Teduglutide, a Novel Analogue of Glucagon-like Peptide 2 (GLP-2), Is Effective and Safe in Reducing Parenteral Support Volume in Short Bowel Syndrome–Intestinal Failure Subjects: Results From a 24-Week, Placebo-Controlled Phase 3 Trial (STEPS)

2011 ◽  
Vol 140 (5) ◽  
pp. S-146 ◽  
Author(s):  
Palle B. Jeppesen ◽  
Marek Pertkiewicz ◽  
Douglas L. Seidner ◽  
Stephen O'Keefe ◽  
Hartmut Heinze ◽  
...  
Keyword(s):  
Short Bowel Syndrome ◽  
Intestinal Failure ◽  
Phase 3 ◽  
Short Bowel ◽  
Parenteral Support ◽  
Glucagon Like Peptide

scholarly journals Intestinal adaptation in short bowel syndrome. What is new?

2018 ◽  
Author(s):  
L Billiauws ◽  
M Thomas
Keyword(s):  
Growth Factor ◽  
Short Bowel Syndrome ◽  
Dietary Intervention ◽  
Intestinal Adaptation ◽  
Intestinal Failure ◽  
Short Bowel ◽  
Energy Recuperation ◽  
Glucagon Like Peptide ◽  
First Cause

Short bowel syndrome is the first cause of intestinal failure, which requires intravenous supplementation (hydro-electrolytic and/or caloric).  Physiological intestinal adaptation occurs 1 to 2 years after resection. This adaptation includes hyperphagia, changes in microbiota, morphological intestinal changes (including hyperplasia), hormonal adaptation... The colon plays a major role and permits hydro-electrolytic and energy recuperation. It is possible to enhance the physiologic adaptation by optimizing the dietary intervention, restoring the continuity and by giving a growth factor treatments such as GLP-2 analog(Glucagon-Like Peptide-2).

Bile acid – farnesoid X receptor – fibroblast growth factor 19 axis in patients with short bowel syndrome: the randomized glepaglutide phase 2 trial

2021 ◽  
Author(s):  
Mark Krogh Hvistendahl ◽  
Rahim Mohammad Naimi ◽  
Svend Høime Hansen ◽  
Jens Frederik Rehfeld ◽  
Hannelouise Kissow ◽  
...  
Keyword(s):  
Bile Acid ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Short Bowel Syndrome ◽  
Farnesoid X Receptor ◽  
Fibroblast Growth ◽  
Phase 2 ◽  
Short Bowel ◽  
Phase 2 Trial ◽  
Fibroblast Growth Factor 19
Sign in / Sign up

Export Citation Format

Share Document